Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.39 |
| ▸ | PDE5A | O76074 | 7/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.34 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21787195 | 0.91 | L3MBTL1 (0.44) | L3MBTL1PDE5AAURKAGUCY1A1GUCY1B1 | |
| SCHEMBL21787287 | 0.88 | L3MBTL1 (0.45) | L3MBTL1PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL21787236 | 0.87 | L3MBTL1 (0.47) | L3MBTL1PDE5AAURKA | |
| SCHEMBL21787380 | 0.87 | L3MBTL1 (0.44) | L3MBTL1PDE5AAURKA | |
| SCHEMBL20161316 | 0.87 | GRIN2B (0.36) | L3MBTL1GRIN1GRIN2BPDE5AGUCY1A1 | |
| SCHEMBL20140411 | 0.84 | L3MBTL1 (0.46) | L3MBTL1PDE5A | |
| SCHEMBL21787225 | 0.83 | L3MBTL1 (0.60) | L3MBTL1PDE5AAURKAP2RX7GUCY1A1 | |
| SCHEMBL24205908 | 0.83 | L3MBTL1 (0.44) | L3MBTL1PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL21787238 | 0.82 | L3MBTL1 (0.49) | L3MBTL1PDE5A | |
| SCHEMBL24040769 | 0.81 | PDE5A (0.44) | L3MBTL1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| WO-2018089330-A2 | SGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | L3MBTL1 4695/4885GRIN1 1488/4885GRIN2B 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.